Heart surgery without a heart-lung machine - 18/11/2026 HeartGate: the safe gateway to the heart For patients with advanced heart failure, a mechanical heart pump can offer a life-saving alternative to heart transplants. As part of the HeartGate project, researchers at the University Medical Center Freiburg are developing an innovative implantation system to insert a heart pump directly into a beating heart. https://www.gesundheitsindustrie-bw.de/en/article/news/heartgate-safe-gateway-heart
Press release - 11/11/2026 Spine tumor surgery: Better preparation with a digital twin How can complex spinal tumor surgeries be planned and prepared more effectively in the future? As part of the IntelliSpine-Recon collaborative project, researchers will develop, among other innovations, a digital twin of the spine and a virtual training environment for surgeons. The junior research consortium, coordinated by the Heidelberg Faculty of Medicine at Heidelberg University, is being carried out in partnership with the KIT. https://www.gesundheitsindustrie-bw.de/en/article/press-release/spine-tumor-surgery-better-preparation-digital-twin
Press release - 09/11/2026 Mirco Friedrich Receives the Peter and Traudl Engelhorn Foundation Award Mirco Julian Friedrich, a physician and cancer researcher at the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Research Institute, and Heidelberg University Hospital (UKHD), is being honored for his outstanding research on the aging immune system and the immune response to blood cancer.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mirco-friedrich-receives-peter-and-traudl-engelhorn-foundation-award
Press release - 04/11/2026 Hahn-Schickard Transfers Joint Venture Shares to Endress+Hauser Five years after the companies were jointly founded, the Endress+Hauser Group has acquired the shares in Endress+Hauser BioSense previously held by Hahn-Schickard. This move marks an important milestone in the successful transfer of microfluidic technologies from research to industrial applications. The technological partnership will continue.https://www.gesundheitsindustrie-bw.de/en/article/press-release/hahn-schickard-transfers-joint-venture-shares-endress-plus-hauser
Press release - 04/11/2026 Molecular guardian inhibits aggressive brain tumor's ability to switch between identities One of the reasons for the high aggressiveness of glioblastomas is their remarkable adaptability. A team led by scientists from the German Cancer Research Center (DKFZ), the EMBL, HITBR*, and the Wellcome Sanger Institute, Cambridge, now describes how glioblastoma cells switch between different states. At the same time, they identified a key factor that, acting as a guardian of cell identity, limits this adaptability.https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-guardian-inhibits-aggressive-brain-tumors-ability-switch-between-identities
Robotics in medicine: initial trials of HASEL technology - 04/11/2026 Using artificial muscles to reduce uncontrolled tremors For people with tremors, even simple everyday tasks can become a challenge. Researchers from Stuttgart and Tübingen are developing a novel assistive system designed to actively suppress these involuntary movements. Initial tests using artificial muscles based on HASEL technology have shown promising results – but there is still a long way to go before the technology is ready for everyday use.https://www.gesundheitsindustrie-bw.de/en/article/news/using-artificial-muscles-reduce-uncontrolled-tremors
Press release - 02/11/2026 Stem Cells in Deep Sleep as a Secret Reserve Researchers at the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have discovered a group of particularly long-lived blood stem cells in mice. These cells remain in a dormant state for an exceptionally long time while retaining their ability to generate new blood cells. This newly discovered cell population may be responsible for sustaining blood regeneration and immune defense throughout a mouse’s entire life.https://www.gesundheitsindustrie-bw.de/en/article/press-release/stem-cells-deep-sleep-secret-reserve
Press release - 02/11/2026 Heidelberger researchers receive Else Kröner memorial fellowships for projects on kidney disease and AI-based diagnostics Why do certain congenital kidney disorders vary so widely in severity among affected individuals? Can AI improve breast cancer diagnostics? These are the questions being addressed in current projects by two early-career researchers at the Heidelberg Faculty of Medicine at Heidelberg University. https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberger-researchers-receive-else-kroner-memorial-fellowships-projects-kidney-disease-and-ai-based-diagnostics
Press release - 29/10/2026 New Approach Could Make Immunotherapy for Blood Cancer More Precise Researchers at the Faculty of Medicine – University of Freiburg have developed a new approach to specifically target an aggressive form of blood cancer while better sparing healthy immune cells. In what is known as T-cell acute lymphoblastic leukemia (T-ALL), cancer cells develop from the body’s own immune defense cells. This complicates treatment, as immunotherapies studied to date can also destroy healthy immune cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-could-make-immunotherapy-blood-cancer-more-precise
Press release - 29/10/2026 VUSE XR closes €1.2 million pre-seed round to scale enterprise mixed reality training VUSE XR today announced the closing of a €1.2 million pre-seed financing round led by IACD, a Düsseldorf-based business angel network. The company develops the VUSE XR Hub, an enterprise software solution for creating and deploying mixed reality training for industrial and life sciences companies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vuse-xr-closes-euro-12-million-pre-seed-round-scale-enterprise-mixed-reality-training
Press release - 28/10/2026 A Discovery in Freiburg Makes Cancer Immunotherapy Better Tolerated A discovery made in Freiburg opens up new treatment options for cancer patients worldwide: Researchers at the Medical Center – University of Freiburg have discovered how severe side effects of cancer immunotherapies can be alleviated using a specialized cell therapy involving treated white blood cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/discovery-freiburg-makes-cancer-immunotherapy-better-tolerated
Press release - 26/10/2026 Multiple sclerosis: New treatment significantly reduces relapses A new treatment could improve care for people with relapsing multiple sclerosis (MS). In two international studies involving a total of 2,007 patients, remibrutinib reduced the annualized relapse rate by 31% to 35% compared with an established MS therapy. New inflammatory brain lesions were also significantly less frequent. In addition, there are indications that the treatment may slow the progression of physical disability.https://www.gesundheitsindustrie-bw.de/en/article/press-release/multiple-sclerosis-new-treatment-significantly-reduces-relapses
Press release - 20/10/2026 How randomness makes artificial vision more reliable Humans are usually remarkably good at recognising objects, even under poor viewing conditions. Artificial vision systems, by contrast, reach their limits more quickly when images are distorted or unfamiliar. Researchers at the Hertie Institute for Clinical Brain Research (HIH) have now investigated what artificial vision systems can learn from the brain.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-randomness-makes-artificial-vision-more-reliable
Prime Vector Technologies is developing a new vaccine platform - 20/10/2026 The ORF platform – one virus, many possibilities Many vaccines effectively deliver an antigen to the desired target site. But what if, at the same time, the immune system could be specifically orchestrated to build broad and comprehensive protection? This idea led to the development of a novel vector platform based on the Orf virus. The work was carried out by the Tübingen-based start-up Prime Vector Technologies.https://www.gesundheitsindustrie-bw.de/en/article/news/orf-platform-one-virus-many-possibilities
Press release - 19/10/2026 New Biotech Master’s Degree Launches at Ulm University: Pharmaceutical and Molecular Biotechnology How do RNA-, protein- or stem cell-based therapies work? How can data science methods from bioinformatics and artificial intelligence be used to develop new pharmaceutical active substances? Students at Ulm University are learning this in the new master’s programme in Pharmaceutical and Molecular Biotechnology (PMB).https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-biotech-masters-degree-launches-ulm-university-pharmaceutical-and-molecular-biotechnology
Press release - 16/10/2026 A new approach to osteoporosis treatment Disabling a bone formation inhibiting protein molecule How can the human body be stimulated to build more bone, thus helping those affected by osteoporosis? Researchers in Ulm have investigated the role played by the protein molecule Axl in this process. Their efforts were successful: in a study, they demonstrated that Axl inhibits bone formation – and that cells produce significantly more bone tissue when the molecule is blocked using medication. There are no discernible harmful side effects. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-osteoporosis-treatment-disabling-bone-formation-inhibiting-protein-molecule
Press release - 16/10/2026 Epilepsy: AI Aims to Improve Treatment with Brain Pacemakers About 250,000 people in Germany live with epilepsy that does not respond adequately to medication. How can their treatment be further improved with a brain pacemaker? As part of the CLOUDIA research project, the Medical Center – University of Freiburg is now collaborating with a medical technology company to develop an AI-supported assistance system for analyzing long-term brain activity data.https://www.gesundheitsindustrie-bw.de/en/article/press-release/epilepsy-ai-aims-improve-treatment-brain-pacemakers
Press release - 15/10/2026 Four Million Euros in EU Funding to Improve Prostate Cancer Care A European research consortium led by the German Cancer Research Center (DKFZ) aims to fundamentally improve the diagnosis and treatment of prostate cancer using AI agents, big data, and patient-centered clinical decision support. The central goal is to detect aggressive tumors early and accurately, reduce unnecessary interventions, and tailor treatment decisions more closely to the individual patient.https://www.gesundheitsindustrie-bw.de/en/article/press-release/four-million-euros-eu-funding-improve-prostate-cancer-care
Event - 18/11/2026 Match Arena Stuttgart, Networking Event https://www.gesundheitsindustrie-bw.de/en/event/match-arena-en
Press release - 08/10/2026 High iron levels may promote the mobility of brain tumor cells Iron is essential for healthy cells. Cancer cells also require this trace element. Researchers in Freiburg have now found evidence that high levels of iron directly in the tumor microenvironment promote the spread of certain cells in a particularly aggressive type of brain tumor known as glioblastoma. In the long term, iron metabolism could therefore serve as a target for more precisely influencing particularly invasive tumor cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-iron-levels-may-promote-mobility-brain-tumor-cells
A revolution in glass processing technology for the medical technology sector - 07/10/2026 The Freiburg-based start-up Glassomer is rethinking materials Glassomer has developed an innovative process for producing pure quartz glass. The result is geometrically complex glass components with micrometre-level precision that can be reproduced consistently at a fraction of the energy cost of conventional glass-melting processes. The company focuses in particular on customised products for diagnostic, therapeutic and microfluidic applications.https://www.gesundheitsindustrie-bw.de/en/article/news/freiburg-based-start-glassomer-rethinking-materials
Press release - 06/10/2026 EXIST funding for xenko start-up team at Ulm University Virtual health platform to encourage more physical activity in the working day The start-up xenko has been awarded an EXIST grant of 143,500 € from the Federal Ministry for Economic Affairs and Energy. The team of founders from Ulm University is developing a digital health platform designed to encourage more physical activity in everyday working life through virtual reality. This development is of interest to companies with occupational health management schemes and, in the long term, to the physiotherapy sector as well.https://www.gesundheitsindustrie-bw.de/en/article/press-release/exist-funding-xenko-start-team-ulm-university-virtual-health-platform-encourage-more-physical-activity-working-day
Press release - 06/10/2026 Harnessing Synthetic Cellular Systems as Immune Cell Boosters How can cell-based immunotherapies for cancer and autoimmune diseases become more widely available in the long term? The SYNTHIA project is addressing this challenge: The Max Planck Institute for Medical Research and the Fraunhofer Institute for Cell Therapy and Immunology IZI are collaborating on new research approaches to advance the development of cell-based immunotherapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/harnessing-synthetic-cellular-systems-immune-cell-boosters
Press release - 05/10/2026 A Matter of Quantity: A Universal Target for CAR-T Cells Against Cancer CAR-T cell therapies have proven successful in treating several types of blood and lymphoid cancers. However, their use in treating other tumors is significantly more challenging, in part because suitable target structures are lacking.https://www.gesundheitsindustrie-bw.de/en/article/press-release/matter-quantity-universal-target-car-t-cells-against-cancer-1
Press release - 05/10/2026 A Matter of Quantity: A Universal Target for CAR-T Cells Against Cancer CAR-T cell therapies have proven successful in treating several types of blood and lymphoid cancers. However, their use in treating other tumors is significantly more challenging, in part because suitable target structures are lacking.https://www.gesundheitsindustrie-bw.de/en/article/press-release/matter-quantity-universal-target-car-t-cells-against-cancer
Press release - 05/10/2026 How blood flow controls liver function The liver is organized into distinct zones in which liver cells perform different functions. The blood vessels of the liver play an important role in this spatial organization: the endothelial cells lining the vessels provide signals that instruct neighboring liver cells and help determine their function. But how do endothelial cells know which signals to produce?https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-blood-flow-controls-liver-function
Event - 24/02/2027 - 25/02/2027 Aktuelle Trends im Biomanufacturing – Erfolgsmodell Kooperation Ulm, Congress/Symposium https://www.gesundheitsindustrie-bw.de/en/event/aktuelle-trends-im-biomanufacturing-erfolgsmodell-kooperation-en
Event - 13/04/2027 - 15/04/2027 DMEA 2027 Munich, Fair https://www.gesundheitsindustrie-bw.de/en/event/dmea-2027-en
Press release - 01/10/2026 New AI Agent to Capture and Analyze Patient Experiences for Healthcare Delivery and Health Systems An international consortium led by researchers at the Heidelberg Faculty of Medicine at Heidelberg University will develop an AI-powered interactive assistant for the analysis of patient experiences over the next four years. The goal is to identify individual burdens and challenges early and comprehensively and make this information actionable for patients, care teams, and health systems.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-ai-agent-capture-and-analyze-patient-experiences-healthcare-delivery-and-health-systems
Press release - 30/09/2026 How cells pass on regulatory information A project funded by the Baden-Württemberg Stiftung at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg is investigating the interplay between RNA modifications and epigenetic mechanisms during cell division – and its potential significance for treatment resistance in cancer.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-cells-pass-regulatory-information
Press release - 25/09/2026 Heidelberg University with Top Placings in latest Shanghai Subject Ranking With clinical medicine and medical technology Heidelberg University is again among the best players in Medical Sciences worldwide. In the Global Ranking of Academic Subjects 2026 clinical medicine rose by one place over last year to rank 17th internationally in clinical medicine and so leads the field in Germany. Medical technology is in 21st place internationally and continues to be ranked third in Germany. https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-university-top-placings-latest-shanghai-subject-ranking
Press release - 24/09/2026 Enzyme Beads for More Sustainable Chemistry Thanks to enzyme-based biocatalysis, an enormous range of pharmaceutical active ingredients and other complex molecules can be synthesized in an environmentally friendly manner. Researchers at the Karlsruhe Institute of Technology (KIT) have now developed a technology that allows to assemble enzymes into millimeter-sized, storable beads. In this process, the enzymes not only act as catalysts but also constitute the beads’ material itself.https://www.gesundheitsindustrie-bw.de/en/article/press-release/enzyme-beads-more-sustainable-chemistry
Press release - 23/09/2026 ViferaXS Raises €12 Million to Advance Phase II Trial in Chronic Lymphocytic Leukemia and Expand Its Oncology Pipeline ViferaXS, a clinical-stage biotechnology company developing peptide-based cancer immunotherapy for hematologic malignancies and solid tumors, today announced the close of the Series A financing round of up to €12 million, including grant funding. The round was led by SPRIND, the German Federal Agency for Breakthrough Innovation, and Huma, with participation from private investors.https://www.gesundheitsindustrie-bw.de/en/article/press-release/viferaxs-raises-euro-12-million-advance-phase-ii-trial-chronic-lymphocytic-leukemia-and-expand-its-oncology-pipeline
Use of health data - 22/09/2026 The digital twin – shaping the future of neonatal medicine Virtually every newborn undergoes routine screening shortly after birth to detect congenital disorders. These examinations have generated a unique wealth of data on early childhood development. However, for many years this valuable resource remained largely untapped. That all changed when researchers in Heidelberg started to use the data to develop a digital twin for newborns. Today, the technology is on the verge of entering clinical practice.https://www.gesundheitsindustrie-bw.de/en/article/news/digital-twin-shaping-future-neonatal-medicine
Press release - 17/09/2026 New technique could make MRI more precise A team of researchers at the University of Stuttgart has developed a new method that could make MRI even more precise by eliminating “dead time,” a key limiting factor in the measurement process, thereby enabling the detection of signals that are lost using conventional methods. This method opens up new possibilities for medical diagnostics and non-destructive materials testing. The research team presents the new approach in Science Advances.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-technique-could-make-mri-more-precise
Event - 06/10/2026 - 08/10/2026 Introduction to Planetary Protection Stuttgart, Workshop https://www.gesundheitsindustrie-bw.de/en/event/introduction-planetary-protection-en
Press release - 16/09/2026 Professor Jakob Nikolas Kather Appointed Hopp Foundation Professor of “Artificial Intelligence in Medicine” and Founding Director of the New Institute for Medical AI (IMAI) in Heidelberg Effective 1 October 2026, Professor Jakob Nikolas Kather will assume the Hopp Foundation Professorship for “Artificial Intelligence in Medicine” at the Heidelberg Faculty of Medicine at Heidelberg University. Associated with the professorship is the establishment of the new Institute for Medical AI (IMAI) at Heidelberg University Hospital, which Professor Kather will lead as its founding director.https://www.gesundheitsindustrie-bw.de/en/article/press-release/professor-jakob-nikolas-kather-appointed-hopp-foundation-professor-artificial-intelligence-medicine-and-founding-director-new-in
Press release - 10/09/2026 New collaboration on DNA nanotechnology Prof. Chunhai Fan, who is a recipient of the Humboldt Research Award, has been conducting research at the University of Stuttgart since June. Fan works closely with Prof. Laura Na Liu of the 2nd Physics Institute. Both researchers are among the world's leading experts in the field of DNA nanotechnology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-collaboration-dna-nanotechnology
Press release - 09/09/2026 International Research on Bioengineering of the Mitochondrial Genome While the cell nucleus contains almost all of the genome, the mitochondria – the powerhouses of the cell – have their own small genetic code. It consists of only 37 genes, which are organized in circular DNA – mtDNA, for short. Defects in the mitochondrial genome are related to incurable neurodegenerative and metabolic diseases, cancer and also aging processes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/international-research-bioengineering-mitochondrial-genome
Press release - 08/09/2026 Quality Over Quantity: New Insights into the Role of Specific CAR T Cells in Cancer Therapy CAR T-cell therapies are used successfully to treat certain blood cancers. However, while some patients respond even to low-dose treatment, others derive no benefit. Researchers from the Heidelberg Faculty of Medicine at Heidelberg University and the Berlin Institute of Health at Charité (BIH) investigated the reasons behind these differences in a collaborative research project.https://www.gesundheitsindustrie-bw.de/en/article/press-release/quality-over-quantity-new-insights-role-specific-car-t-cells-cancer-therapy
Press release - 08/09/2026 Heisenberg Professorship for Aurélie Ernst With funding from the German Research Foundation’s (DFG) Heisenberg Program, DKFZ researcher Aurélie Ernst aims to investigate how massive changes in the genome contribute to the development of cancer. Her research focuses on a phenomenon known as chromothripsis - a catastrophic event in the genome in which chromosomes break apart and are reassembled incorrectly.https://www.gesundheitsindustrie-bw.de/en/article/press-release/heisenberg-professorship-aurelie-ernst
Dossier - 08/09/2026 AI and robotics are shaping the future of medicine Artificial intelligence and robotics are playing an increasingly important role in healthcare, as in many other areas of life. They offer considerable potential to improve medical care, but require an ethically responsible approach.https://www.gesundheitsindustrie-bw.de/en/article/dossier/ai-and-robotics-are-shaping-future-medicine
Event - 13/05/2027 - 15/05/2027 REHAB 2027 Karlsruhe, fair https://www.gesundheitsindustrie-bw.de/en/event/rehab-2027-en
Press release - 03/09/2026 Triple ERC Success at the German Cancer Research Center Three researchers at the German Cancer Research Center (DKFZ) have each been awarded a Starting Grant from the European Research Council (ERC) this year. Daniel Kirschenbaum, Lena Kutscher, and Michael Scherer impressed the ERC with their innovative research approaches to fundamental questions in cancer medicine.https://www.gesundheitsindustrie-bw.de/en/article/press-release/triple-erc-success-german-cancer-research-center
Press release - 03/09/2026 ERC Starting Grant for Heidelberg Neurologist and Neuroscientist Dr. Dr. Varun Venkataramani Cells of the highly aggressive brain tumor glioblastoma exhibit predatory behavior: they exploit signaling between healthy neurons and internalize portions of their contact sites. Dr. Dr. Varun Venkataramani of the Heidelberg Medical Faculty of Heidelberg University, and his research team, will investigate how glioblastoma cells benefit from this process and whether it may represent a novel therapeutic target.https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-starting-grant-heidelberg-neurologist-and-neuroscientist-dr-dr-varun-venkataramani
Funding FIGHT KIDS CANCER 2026-2027 Competitive Call Funding programme, Funded by: Fight Kids Cancer, sb_search.searchresult.label.programSubmissionDate: 13/10/2026 https://www.gesundheitsindustrie-bw.de/en/database/funding/fight-kids-cancer-2026-2027-competitive-call
Press release - 01/09/2026 Early Detection of COPD: A Study in Freiburg Investigates a New Treatment Coughing, phlegm, and shortness of breath can be early signs of COPC. In COPD, the airways are permanently narrowed, making it harder to breathe. The most significant risk factor is long-term smoking. The CHRONOS study conducted by the Department of Pneumology at the Medical Center – University of Freiburg provides evidence that changes in the lungs can already be detected before a standard pulmonary function test confirms the airway narrowing.https://www.gesundheitsindustrie-bw.de/en/article/press-release/early-detection-copd-study-freiburg-investigates-new-treatment
Event - 06/11/2026 Health Innovation Nexus Strasbourg, France, Registration deadline: 23/10/2026https://www.gesundheitsindustrie-bw.de/en/event/health-innovation-nexus-en
Press release - 28/08/2026 Outstanding success for Ulm’s quantum physics QuantERA funds four teams Research into quantum technology by four teams at Ulm University is being funded as part of the European QuantERA programme. This is more than at any other German university. The projects focus, for example, on more robust quantum computers and innovative medical diagnostic methods.https://www.gesundheitsindustrie-bw.de/en/article/press-release/outstanding-success-ulms-quantum-physics-quantera-funds-four-teams
Panosome GmbH – a parasite as the basis for innovative immunotherapies - 26/08/2026 Reaching the unreachable: new approaches to challenging drug targets Modern medicines act with remarkable precision. Antibodies, for example, recognise their molecular targets much like a key fits into its corresponding lock. However, certain targets like small molecules or carbohydrates remain difficult to target. The start-up Panosome aims to eliminate these blind spots with a novel immunotherapy platform that harnesses sophisticated masters of immune evasion: trypanosomes.https://www.gesundheitsindustrie-bw.de/en/article/news/reaching-unreachable-new-approaches-challenging-drug-targets
Press release - 25/08/2026 Revier Therapeutics Launches with €6 Million Seed Financing to Pioneer Class IIa HDAC Inhibitors for Cardiometabolic Disease Revier Therapeutics, today announced the closing of a EUR 6 million seed financing and the launch of its operations. The Company has established the first therapeutic approach to selectively target class IIa histone deacetylases (HDACs) for the treatment of cardiometabolic diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/revier-therapeutics-launches-euro-6-million-seed-financing-pioneer-class-iia-hdac-inhibitors-cardiometabolic-disease
Funding Next Frontier Robotics Competition, Funded by: SPRIN-D, sb_search.searchresult.label.programSubmissionDate: 22/10/2026 https://www.gesundheitsindustrie-bw.de/en/database/funding/next-frontier-robotics-en
Event - 27/11/2026 Targeted Drug Delivery Ulm, Registration deadline: 20/11/2026, Kongress/Symposium https://www.gesundheitsindustrie-bw.de/en/event/targeted-drug-delivery-en
Event - 01/10/2026 Swiss Nordic Bio 2026 Zurich, Switzerland, Registration deadline: 30/09/2026, Conference https://www.gesundheitsindustrie-bw.de/en/event/swiss-nordic-bio-2026-en
Funding Recoding Medicine Competition, Funded by: SPRIN-D, sb_search.searchresult.label.programSubmissionDate: 16/10/2026 https://www.gesundheitsindustrie-bw.de/en/database/funding/recoding-medicine-en
Press release - 18/08/2026 A local barrier against respiratory viruses How can a respiratory virus be stopped before it spreads throughout the body? In the MucoShield project, Prime Vector Technologies, the NMI Tübingen, and Fraunhofer IGB are developing an intranasal vaccine candidate against human metapneumovirus (HMPV), which causes hundreds of thousands of cases of severe respiratory disease worldwide each year – especially among children, older people, and immunocompromised individuals.https://www.gesundheitsindustrie-bw.de/en/article/press-release/local-barrier-against-respiratory-viruses
Event - 18/11/2026 BW-UK networking evening at MEDICA 2026 Baden-Württemberg joint booth G24 in hall 15, trade-fair MEDICA, Registration deadline: 16/11/2026, Messe https://www.gesundheitsindustrie-bw.de/en/event/bw-uk-networking-evening-medica-2026
Event - 04/11/2026 Lunch & Learn ahead of MEDICA: Collaborative R&D funding for healthcare innovation in UK and Germany Online (Webex), Registration deadline: 02/11/2026, information event https://www.gesundheitsindustrie-bw.de/en/event/lunch-und-learn-ahead-medica-collaborative-r-und-d-funding-healthcare-innovation-uk-and-germany
Press release - 13/08/2026 PRAME-specific T-cell therapy in an adolescent with metastatic kidney tumor Researchers and physicians at the Hopp Children's Cancer Center Heidelberg (KiTZ) and other leading cancer centers report an exceptional treatment success in an adolescent with an advanced, therapy-resistant kidney tumor. Using a novel, personalized T-cell therapy, they succeeded in completely pushing back the tumor disease despite multiple metastases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/prame-specific-t-cell-therapy-adolescent-metastatic-kidney-tumor
The NanoLYRIC project: nanoparticles as drug carriers - 13/08/2026 Radiation-activated local chemotherapy Conventional chemotherapy is associated with severe side effects because cytotoxic drugs act on the whole body. Researchers at the Karlsruhe Institute of Technology and the University Medical Centre Göttingen, in collaboration with Aalen University of Applied Sciences, are developing a novel approach in which a chemotherapeutic agent encapsulated in nanoparticles is released locally and selectively only upon targeted irradiation of the tumour.https://www.gesundheitsindustrie-bw.de/en/article/news/radiation-activated-local-chemotherapy
Press release - 12/08/2026 Industrial-scale biotech production of proteins and vitamins economically viable Researchers are developing biotechnological processes that enable microbes to produce proteins and vitamins for human consumption using basic chemical ingredients, such as carbon dioxide, hydrogen and oxygen – entirely bypassing livestock farming and agriculture. Because these methods also require energy input, they are popularly called “power-to-protein” and “power-to-vitamin” processes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/industrial-scale-biotech-production-proteins-and-vitamins-economically-viable
Press release - 11/08/2026 Programming membrane transport New in Nature Nanotechnology: A DNA origami nanosyringe introduces mechanically controlled molecular transport into synthetic cells. This opens new opportunities for synthetic biology, engineered biointerfaces and molecular therapeutics.https://www.gesundheitsindustrie-bw.de/en/article/press-release/programming-membrane-transport
Press release - 10/08/2026 Immune Cells in Bone Marrow Cancer: Limited Defense Readiness A team led by researchers from the German Cancer Research Center, the HI-STEM* Stem Cell Institute, and Medical Clinic V at Heidelberg University Hospital has characterized T cells in the bone marrow in cases of multiple myeloma and acute myeloid leukemia: A specific group of tumor-reactive T cells can recognize and fight cancer cells, but is often not sufficiently activated. Nevertheless, the number of these cells influences the prognosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immune-cells-bone-marrow-cancer-limited-defense-readiness
Press release - 07/08/2026 Can Protein Building Blocks Protect Against Vascular and Kidney Damage? Researchers from the Medical Faculty Heidelberg, the Medical Faculty Mannheim, and the Centre for Organismal Studies at Heidelberg University have launched a new research project investigating so-called dipeptides. The consortium aims to determine which dipeptides have the strongest protective effects and how they could be harnessed in future therapies for vascular and kidney diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/can-protein-building-blocks-protect-against-vascular-and-kidney-damage
Press release - 05/08/2026 Center of Excellence in Oncology: NCT Heidelberg and Mannheim Cancer Center Receive Joint Funding The National Center for Tumor Diseases (NCT) Heidelberg and the Mannheim Cancer Center (MCC) are receiving joint funding as a Center of Excellence in Oncology for the first time. German Cancer Aid is providing 4.8 million euros over four years for the new consortium.https://www.gesundheitsindustrie-bw.de/en/article/press-release/center-excellence-oncology-nct-heidelberg-and-mannheim-cancer-center-receive-joint-funding
Press release - 03/08/2026 ERC Starting Grant awarded for research into Post-Traumatic Stress Disorder Over the next five years, Dr. Mykhailo Batiuk and his research group at the Heidelberg Faculty of Medicine at Heidelberg University will investigate the biological mechanisms underlying post-traumatic stress disorder. The European Research Council (ERC) is supporting the project with an ERC Starting Grant worth approximately €1.4 million.https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-starting-grant-awarded-research-post-traumatic-stress-disorder
Press release - 31/07/2026 A new genetic tool helps researchers uncover the logic of gene regulation Researchers use synthetic biology approaches to test hundreds of DNA sequences for their effect on regulating gene expression. The human genome contains over 20,000 genes. However, at any given time and in a given cell, only a fraction of them are active. Researchers from EMBL Heidelberg’s Krebs Group have come up with an innovative experimental approach to understand how cells determine which genes to turn on and when.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-genetic-tool-helps-researchers-uncover-logic-gene-regulation
Press release - 31/07/2026 New insights into Malaria research: How molecular tethers and Asynchronous replication drive parasite proliferation Researchers from Heidelberg University’s Faculty of Medicine, Harvard Medical School, and the German Cancer Research Center (DKFZ) have uncovered key mechanisms underlying the proliferation of the malaria parasite Plasmodium. The molecular processes that govern the formation of infectious daughter parasites and new nuclei are essential for parasite survival and may therefore represent targets for future antimalarial therapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-insights-malaria-research-how-molecular-tethers-and-asynchronous-replication-drive-parasite-proliferation
Event - 03/11/2026 - 05/11/2026 Trinational Health Tech Days 7 Strasbourg, France and online, Conference and networking event https://www.gesundheitsindustrie-bw.de/en/event/trinational-health-tech-days-7-en
Event - 06/10/2026 - 07/10/2026 Quantum Effects 2026 Stuttgart, Conference & Exhibition https://www.gesundheitsindustrie-bw.de/en/event/quantum-effects-2026-en
Press release - 30/07/2026 The University of Freiburg is promoting knowledge transfer and networking at the Käpsele Innovation Festival The University of Freiburg took part in this year’s Käpsele Innovation Festival with contributions from the fields of research and entrepreneurship promotion. The event focused on future-oriented topics such as Artificial Intelligence, cybersecurity and resilience, as well as on fostering dialogue and networking amongst stakeholders from the worlds of academia, business and politics.https://www.gesundheitsindustrie-bw.de/en/article/press-release/university-freiburg-promoting-knowledge-transfer-and-networking-kaepsele-innovation-festival
Press release - 29/07/2026 ERC Synergy Grant has started The international research project MitoContact is dedicated to investigating how organelles within a cell communicate and interact with other cellular components. Kai Johnsson, Director at the Max Planck Institute for Medical Research, has received funding from the ERC for this project. The findings are expected to provide new insights into fundamental cellular processes and contribute to a better understanding of various diseases. https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-synergy-grant-has-started
Event - 03/09/2026 International NAKO Conference 2026 Munich, Kongress/Symposium https://www.gesundheitsindustrie-bw.de/en/event/international-nako-conference-2026-en
EMUNO Therapeutics: the innate immune system as a new approach to cancer treatment - 29/07/2026 Activation of macrophages: a key factor in the fight against colorectal cancer The mobilisation of the body’s own immune system through immune checkpoint inhibitors has revolutionised cancer therapy. However, the majority of solid tumours are able to evade immune surveillance. These so-called 'cold' tumours contain too few immune cells to respond effectively to current immunotherapies. This is where the Freiburg-based biotech start-up EMUNO Therapeutics GmbH comes in.https://www.gesundheitsindustrie-bw.de/en/article/news/activation-macrophages-key-factor-fight-against-colorectal-cancer
Press release - 24/07/2026 Changes in brain state influence the readiness to form memories Most everyday moments are quickly forgotten, while others stay with us for a lifetime. How the brain determines which memories are retained and which are lost remains an open question. A neuroscience team at the University of Tübingen, has found that spontaneous fluctuations in the brain’s internal state influence how ready the memory system is to store new information. https://www.gesundheitsindustrie-bw.de/en/article/press-release/changes-brain-state-influence-readiness-form-memories